|
|
News Breaks | | | | June 25, 2012 | | 09:04 EDT |  | GTXI | GTx announces presentation of Phase IIb enoborsarm study results
GTx, Inc. announced that in a Phase IIb clinical study of enobosarm, there was significantly improved physical function after 16 weeks of treatment, compared to placebo, in both hypogonadal and eugonadal subjects. The study met its primary endpoint of absolute change in total lean body mass compared to placebo after 16 weeks of treatment. The data were reported by Adrian Dobs, M.D., M.H.S., professor of medicine and oncology, and Vice-Chair of the Department of Medicine, Faculty Development at The Johns Hopkins University Medical School, during the 2012 Annual Meeting of The Endocrine Society. Enobosarm is currently being evaluated in two pivotal Phase III clinical trials. | |
|
News For GTXI From The Last 14 Days Check below for free stories on GTXI the last two weeks. |
|
|
| There are no results for GTXI |
|
|
|
|
|
|
